PROSPERO: A phase 3 randomized, placebo (Pbo)-controlled study of amezalpat (TPST-1120), a peroxisome proliferator-activated receptor a (PPARα) inhibitor, in combination with atezolizumab + bevacizumab (AB) for patients (pts) with unresectable or metastatic hepatocellular carcinoma (mHCC) not previously treated with systemic therapy.

Authors: Mark Yarchoan, Stephen Lam Chan, Julien Edeline, Daneng Li, Darrin Bomba, Yonchu Jenkins, Steven Smith, Nathan Standifer, Arndt Vogel, Sam H. Whiting

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4214

Source: Full article

---

Abstract

TPS4214